

EVALUATION OF USE, EFFECTIVENESS AND SAFETY OF ISAVUCONAZOL



C.A. ALONSO PERALTA¹, C.M. VALENCIA SOTO¹, A. ILLARO URANGA¹, R.M. GONZALEZ FRANCO¹, B. ROGADO VEGAS¹, J. CASANOVA VÁZQUEZ¹, P. DEL RIO ORTEGA¹, M. RIOJA CARRERA¹, I. ARAGON GRACIA¹, L. PEREZ-PERIAÑEZ ORILLO¹, M. VALERO DOMÍNGUEZ¹.

¹HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA, FARMACIA HOSPITALARIA, SANTANDER, SPAIN.



@carloalo93




BACKGROUND AND IMPORTANCE

Isavuconazole is an authorised antifungal for the treatment of invasive fungal infection (IFI) by *Aspergillus* in adult patients in which amphotericin B is not appropriate.

AIM AND OBJETIVES

To assess the conditions of use, effectiveness of isavuconazole (ISA) versus voriconazole (VORI) compared to the SECURE pivotal study in a third level hospital and describe adverse events in ISA group.



MATERIAL Y METHODS

| DEMOGRAPHIC DATA | EFFECTIVENESS | ADVERSE EVENTS (AEs) | STATISTICAL ANALYSIS |
|---|--|---|----------------------|
| <ul style="list-style-type: none"> Sex Age Type of infection Causative fungus Duration of treatment Immunosuppressive treatment | <p>Clinical response (CR):</p> <ul style="list-style-type: none"> Resolution of symptoms No need for subsequent antifungals <p>Data compilation was carried out through assisted electronic prescription and electronic medical history</p> | Worsening of underlying symptoms with ISA | R-commander |

RESULTS

DEMOGRAPHIC DATA

| TREATMENT | NUMBER OF PATIENTS | MALE/FEMALE | MEAN AGE | DAYS OF TREATMENT |
|--------------|--------------------|-------------|-----------------|-------------------|
| ISAVUCONAZOL | 10 | 9/1 | 54,6 (46,25-60) | 49 (14 – 73,5) |
| VORICONAZOL | 20 | 15/5 | 66,5 (58-78,5) | 15 (11 – 44,5) |

TYPE OF INFECTION

| INVASIVE FUNGAL INFECTION (IFI) TESTS BY CULTURES | PROBABLE IFI |
|---|--|
| <ul style="list-style-type: none"> <i>Aspergillus fumigatus</i> (2 vs. 8) <i>A. flavus</i> (2 vs. 0) <i>A. niger</i> (1 vs. 0) <i>A. terreus</i> (0 vs. 2) <i>A. sydowii</i> (0 vs. 1) <i>Candida lusitanae</i> (1 vs. 0) <i>Lichtheimia</i> (1 vs. 0) | <ul style="list-style-type: none"> Positive galactomannan CT image |


CONCLUSION AND RELEVANCE

Among our population, Isavuconazole was a relatively effective and safe alternative, without relevant differences compared to voriconazole in terms of effectiveness, according to the SECURE pivotal study. A larger sample size would be necessary to verify this data.

REFERENCES

Informe de Posicionamiento Terapéutico de isavuconazol (Cresemba®) en el tratamiento de la aspergilosis invasora y la mucormicosis [Internet]. Disponible en: <https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-isavuconazol-Cresemba-aspergilosis-mucormicosis.pdf>

EFFECTIVENESS



NUMBER OF AEs

